Phase III trial results of novel triple combination pill for hypertension published in The Lancet
October 18, 2024 07:00 ET
|
George Medicines
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced blood pressure and improved control rates vs dual...
E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in Resistant Hypertension With Support of Latest Investment
October 08, 2024 09:00 ET
|
E-Star Biotech
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...
Amwell expands clinical programs portfolio to include Hello Heart cardiovascular health risk management solution
October 08, 2024 07:05 ET
|
Amwell
Amwell today announced Hello Heart is a partner in the Amwell clinical programs portfolio available on the Amwell Converge™ platform.
Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress
September 24, 2024 07:00 ET
|
George Medicines
London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, today announced the presentation...
Angina Global Market Report 2024: A $13.61 Billion Market in 2028, Registering a Compound Annual Growth Rate (CAGR) of 6.2%
September 04, 2024 09:26 ET
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Angina Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.The angina market size has grown strongly in recent years, from...
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
August 31, 2024 03:54 ET
|
George Medicines
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...
Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension
August 19, 2024 09:00 ET
|
Recor Medical
Palo Alto, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) greatly appreciate the American...
George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program
August 06, 2024 07:00 ET
|
George Medicines
George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program ...
First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension with Ultrasound Renal Denervation
July 25, 2024 10:00 ET
|
Recor Medical
Palo Alto, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the first patients...
Ambulatory Blood Pressure Monitoring Devices Market Predicted to Hit USD 2.58 billion, at a CAGR of 8.2% from 2024 to 2032- Report by Polaris Market Research (PMR)
May 08, 2024 08:40 ET
|
Polaris Market Research & Consulting LLP
New York, May 08, 2024 (GLOBE NEWSWIRE) -- Market Explanation: The Global Ambulatory Blood Pressure Monitoring Devices Market was valued at USD 1.27 billion in 2023 and is anticipated to generate...